RxDoctor Payments Data

Allison Manning, APRN

Family · Jackson, KYNPI 1477818896

Payments from drug & device makers

$2,427in general payments, 2019–2025

Across 148 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Novo Nordisk$385
  • AstraZeneca$363
  • GSK$274
  • Bayer$120
  • Boehringer Ingelheim$113
  • plus $561 from 18 others

What the payments were for

  • Food & beverage$2,415100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,427 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,622
Medicare patients
50
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$156,105
JardianceEmpagliflozin66$104,100
MounjaroTirzepatide74$92,560
FarxigaDapagliflozin Propanediol74$91,289
EliquisApixaban76$83,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$70,181
JanuviaSitagliptin Phosphate52$67,796
TrulicityDulaglutide46$64,236
XifaxanRifaximin19$60,226
LinzessLinaclotide48$57,615
XareltoRivaroxaban44$41,657
EnbrelEtanercept11$38,113
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$28,282
Tresiba Flextouch U-200Insulin Degludec20$26,998
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$26,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$385$184,192162 claims
Lilly USA, LLCMounjaro, Trulicity$57$156,795120 claims
Boehringer IngelheimJardiance, Tradjenta$113$117,81181 claims
AstraZenecaFarxiga, Breztri Aerosphere$363$103,98892 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$274$98,56189 claims
PfizerEliquis$19$83,74576 claims
MerckJanuvia$14$67,79652 claims
AbbVieLinzess, Synthroid$610$61,974125 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$16$60,22619 claims
AmgenEnbrel$75$38,11311 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$44$15,40618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Jackson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →